Research

Cellular

Gastrointestinal side effects from tirzepatide are common but mild to moderate, with less than 5% treatment discontinuation.

Practitioners should be aware of potential mild gastrointestinal side effects when prescribing tirzepatide.

StrongSupportsmedium confidence
Gastrointestinal side effects (nausea, diarrhea, constipation) were common but mild to moderate, with <5% treatment discontinuation.
Mohammed Sallam et al. · Obesities · 2025

Why this rating

The claim is based on synthesized evidence from clinical studies.

Source

Efficacy and Safety of Tirzepatide for Weight Management in Non-Diabetic Obese Individuals: A Narrative Review

Mohammed Sallam et al. · Obesities · 2025

DOI 10.3390/obesities5020026

Meta-analysisCited 7×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →